News
Eli Lilly looks set to steal Novo Nordisk’s weight-loss crown
The momentum is now with Lilly. Visible Alpha, a data firm, expects its sales of obesity drugs to overtake Novo’s by 2027 (see chart 2). Lilly’s edge rests on a more effective drug, better execution, keener pricing and a stronger pipeline.
Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.
Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...
Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights ...
Novo Nordisk's (NVO ... Hims & Hers (HIMS), to increase access to Wegovy. Novo also scored an exclusive deal to be listed as the preferred weight-loss drug for coverage on CVS's (CVS) ...
Novo Nordisk on Tuesday said it will offer its weight loss drug Wegovy through telehealth providers Hims & Hers Health, Ro and LifeMD to expand access to the blockbuster treatment now that ...
3don MSN
A new generation of GLP-1 drugs promising fast results continues to rock the weight loss industry, which has emphasized ...
Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback